TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25857271
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol group (n=46) consuming vegetable-oil spread enriched with plant stanols 3 g/day for 6 months
Study: 21427402
Drug: Abacavir therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir therapy
Study: 21427402
Drug: No abacavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: No abacavir therapy
Study: 19773678
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (clarithromycin and rifabutin)
Study: 15221494
Drug: Alfacalcidol 1
Normalized name: alfacalcidol 1 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol 1 micro g/day with calcium for 6 months
Study: 11592566
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy at a dose of 1.5 mg/m2/day
Study: 11592566
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy at a dose of 0.3 mg/m2/day
Study: 11592566
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy (any dose)
Study: 11592566
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy at a dose of >0.3 mg/m2/day
Study: 11592566
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy at a dose of <0.3 mg/m2/day
Study: 7978145
Drug: Thiopentone 100
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 100 mg
Study: 7978145
Drug: Lignocaine 20
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 20 mg
Study: 7978145
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline 4 ml
Study: 2659747
Drug: Intermittent cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent cisplatin (CDDP 60 mg/m2 day 1 and VP16 120 mg/m2 day 1‐3 every 3‐4 weeks)
Study: 2659747
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin (CDDP 20 mg/m2 and VP16 120 mg/m2)
Study: 28866621
Drug: Just-in-Time (JIT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Just-in-Time (JIT) intervention using a portable, bedside computer-based procedural adjunct
Study: 15513250
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of space-based and object-based manipulations
Study: 9260010
Drug: 5 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg.kg‐1 thiopentone iv, isoflurane/N2O maintenance
Study: 9260010
Drug: 3 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg.kg‐1 propofol iv, propofol/N2O maintenance (10‐14 mg.kg‐1.hr‐1)
Study: 9260010
Drug: 3 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg.kg‐1 propofol iv, propofol/air/O2 maintenance (10‐14 mg.kg‐1.hr‐1)
Study: 8288071
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of diuretic therapy
Study: 3548734
Drug: fenofibrate 300
Normalized name: fenofibrate 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenofibrate 300 mg/day
Study: 29625879
Drug: Tivantinib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib (120 mg twice daily)
Study: 28662956
Drug: Topical TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TXA (tTXA)
Study: 18444945
Drug: TNF-alpha G-308A
Normalized name: alpha-Tocopherolquinone
DrugBank: Tocopherylquinone (DB14094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-alpha G-308A with at least one A allele
Study: 11382894
Drug: GHRH (4x50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (4x50 microgram, at hourly intervals between 2200 and 0100 h)
Study: 9149741
Drug: Etoposide (ETOP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (ETOP), Ifosfamide (IFOS), and Vincristine (VCR) with hyperfractionated radiation therapy (XRT)
Study: 7957372
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose oral steroids (oral prednisone: 20‐40 mg)
Study: 3296841
Drug: Methylprednisolone pulse
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone pulse therapy (MPPT) (1000 mg daily for 3 days)
Study: 3296841
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of methylprednisolone (MP) (50 mg daily gradually decreased to zero over 3 weeks)
Study: 28745667
Drug: Cytoflavin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (20 ml in 200 ml of 5% glucose solution)
Study: 17151163
Drug: Internet-based bibliotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based bibliotherapy self-help program with short weekly telephone calls
Study: 12969696
Drug: Transdermal E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal E(2) (50 microg)
Study: 12969696
Drug: Oral E(2)
Normalized name: Aquasol E Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E(2) (1 mg)
Study: 12969696
Drug: Oral E(2)
Normalized name: Aquasol E Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E(2) (1 mg) combined with gestodene (25 microg)
Study: 6366138
Drug: Intrathecal methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal methotrexate dosage regimen derived from CNS volume considerations (CCG-160 series)
Study: 6366138
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with cranial irradiation (2400 rads) and intrathecal methotrexate (12 mg/m2 six times during consolidation) (CCG-141)
Study: 6366138
Drug: Maintenance intrathecal
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance intrathecal chemotherapy
Study: 3512188
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms of fenoterol by metered-dose inhaler
Study: 3512188
Drug: 400 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms of fenoterol by metered-dose inhaler
Study: 21208574
Drug: eszopiclone cotherapy
Normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eszopiclone cotherapy with SSRI (3 mg/d)
Study: 12734787
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg, TID, over 90 days
Study: 10952250
Drug: 3 million
Normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 million units of IFN twice a day
Study: 2952685
Drug: Erythromycin 2%
Normalized name: ERYTHROMYCIN 2% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 2% gel
Study: 24612414
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1mg/kg loading dose prior to incision, continuous dose of 1mg/kg/h for 24h)
Study: 24612414
Drug: Placebo (5mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5mL saline loading dose, continuous dose of 90mg ketorolac in 240mL saline)
Study: 20958890
Drug: Zinc (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (90 mg)
Study: 16892428
Drug: Heparin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin with GP IIb/IIIa inhibition
Study: 12562653
Drug: Modified CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified CHOP (cyclophosphamide 600 mg/m² i.v., doxorubicin 30 mg/m² i.v., vincristine 1 mg i.v. on day 1 with prednisolone 20 mg bd for days 1-5) every 21 days
Study: 12562653
Drug: MCOP (mitozantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCOP (mitozantrone 10 mg/m² i.v. substituted for doxorubicin)
Study: 10868022
Drug: Day-patient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day-patient treatment
Study: 26001996
Drug: Sequential injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential injections of lidocaine 1% plain followed by bupivacaine 0.25% 1h later
Study: 19620518
Drug: Fine particles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fine particles (150 microg/m(3)) plus ozone (120 parts per billion) for 2 hours with Bosentan (250 mg) pretreatment
Study: 19620518
Drug: Fine particles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fine particles (150 microg/m(3)) plus ozone (120 parts per billion) for 2 hours with Vitamin C (2 g) pretreatment
Study: 10856394
Drug: Celiprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (100 mg)
Study: 9200388
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of nicorandil (2 mg)
Study: 8268898
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose diuretic therapy
Study: 2871219
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ketobemidon
Study: 2871219
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg indomethacin
Study: 24881730
Drug: Enzalutamide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide (160 mg once daily)
Study: 21782923
Drug: WM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: WM therapy
Study: 21782923
Drug: CM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM therapy
Study: 20145433
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg benidipine once daily (n = 20, group A)
Study: 15823831
Drug: estradiol 2
Normalized name: estradiol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: estradiol 2 mg/norethisterone acetate 1 mg (E2/NETA)
Study: 11916779
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (MB) 1.5 mg/kg before graft reperfusion
Study: 9893773
Drug: Low-dose formoterol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose formoterol Turbuhaler 6 micrograms b.i.d.
Study: 9893773
Drug: Terbutaline 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 0.5 mg q.i.d.
Study: 1679391
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA, 450 mg daily)
Study: 7060823
Drug: Ibuprofen (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (900 mg daily)
Study: 22572632
Drug: Stretching control
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretching control treatment (n=16)
Study: 19619443
Drug: TP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP regimen (docetaxel 70 mg/m² on Day 1 and DDP 80 mg/m² on Day 2 for induction; docetaxel 60 mg/m² on Day 1 and DDP 80 mg/m² on Day 2 for concurrent chemotherapy)
Study: 19619443
Drug: DDP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDP regimen (DDP 80 mg/m² on Day 1 for concurrent chemotherapy)
Study: 11495215
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive users (nonsmokers)
Study: 11495215
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum administration
Study: 2893410
Drug: Suriclone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suriclone (2 mg/day)
Study: 2893410
Drug: Diazepam (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (25 mg/day)
Study: 27723637
Drug: 0.2% hyaluronan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% hyaluronan gel adjunctive to scaling and root planing
Study: 15928070
Drug: High-dose carboplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose carboplatin, etoposide and cyclophosphamide (CarboPEC) with haematopoietic stem cell support (arm B)
Study: 15928070
Drug: Conventional salvage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional salvage chemotherapy (four cycles of cisplatin, ifosfamide and etoposide or vinblastine) (arm A)
Study: 12802484
Drug: Cefazolin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (50 mg)
Study: 8712441
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron (0.1 mg/kg for children ≤ 40 kg; 4 mg for children > 40 kg)
Study: 1905476
Drug: Whole milk
Normalized name: Calcium fortified whole milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole milk (50 g lactose/L)
Study: 1905476
Drug: Acidified milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidified milk (24 g lactose/L)
Study: 29856692
Drug: Obinutuzumab (G)
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab (G) 1,000 mg on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles for six to eight cycles
Study: 29856692
Drug: Rituximab (R)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (R) 375 mg/m2 on day 1 of each cycle for six to eight cycles
Study: 29856692
Drug: Obinutuzumab (G)
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab (G) plus chemotherapy (bendamustine)
Study: 29856692
Drug: Obinutuzumab (G)
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab (G) plus chemotherapy (CHOP)
Study: 29856692
Drug: Obinutuzumab (G)
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab (G) plus chemotherapy (CVP)
Study: 29856692
Drug: Chemotherapy (CHOP)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CHOP)
Study: 29856692
Drug: Chemotherapy (bendamustine)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (bendamustine)
Study: 16386090
Drug: Unfixed combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfixed combination therapy of 0.5% timolol maleate and 1% dorzolamide hydrochloride
Study: 27098455
Drug: Supervised weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Supervised weekly exercise from the 20th week of pregnancy onwards
Study: 27098455
Drug: Supervised weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Supervised weekly exercise
Study: 25714880
Drug: High-dose rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rocuronium (1.2 mg/kg)
Study: 25714880
Drug: Conventional-dose rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose rocuronium (0.6 mg/kg)
Study: 24091981
Drug: Doxorubicin (Dox)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (Dox) and ifosfamide (Ifo) followed by high dose chemotherapy with ifosfamide, carboplatin, etoposide (HD-ICE) plus peripheral blood stem cell transplantation (PBSCT)
Study: 24091981
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy with ifosfamide, carboplatin, etoposide (HD-ICE)
Study: 24091981
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy plus consolidation HD-ICE
Study: 24091981
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose chemotherapy plus external beam radiation therapy (EBRT)
Study: 19620427
Drug: 0.1% barium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% barium sulfate oral suspension (1,350 mL over 60-75 minutes)
Study: 19620427
Drug: 0.1% barium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% barium sulfate oral suspension
Study: 19620427
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral contrast material
Study: 12935792
Drug: Tolperisone hydrochloride
Normalized name: Tolperisone hydrochloride
DrugBank: Tolperisone (DB06264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolperisone hydrochloride (150 mg) three times daily for 8 days
Study: 10714424
Drug: Zanamivir (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanamivir (10 mg as dry powder, 2 x 5 mg blisters via Diskhaler, twice daily on day 1 and four times daily from day 2 to day 14)
Study: 8815686
Drug: Interferon‐alpha therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon‐alpha therapy
Study: 8815686
Drug: Therapeutic vaccines
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic vaccines and combination therapies
Study: 1382256
Drug: Melatonin (MLT)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin (MLT) 10 mg/day orally at 7.00 p.m.
Study: 3910548
Drug: Econazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Econazole (2 X 150 mg pessaries)
Study: 3910548
Drug: Isoconazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoconazole (2 X 300 mg pessaries)
Study: 29285709
Drug: IWT +
Normalized name: Ibuprofen and Tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IWT + dried tofu intake (DTG, n = 16; 111 kcal, 9.6 g protein, 6.0 g fat, and 4.6 g carbohydrate)
Study: 29285709
Drug: IWT +
Normalized name: Ibuprofen and Tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IWT + placebo intake (PLG, n = 16; 108 kcal, 0.2 g protein, 5.5 g fat, and 14.4 g carbohydrate)
Study: 22900547
Drug: Topical 0.05%
Normalized name: ingenol topical 0.05% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.05% cyclosporine A (CsA) eye drops for an average duration of 5.1 ± 3.5 months (1 ‐ 13 months)
Study: 8549944
Drug: azathioprine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: azathioprine (2.5 mg/kg)
Study: 90964
Drug: Alprenolol (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprenolol (5-10 mg intravenously, followed by 200 mg twice a day orally)
Study: 27637734
Drug: Intravenous pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pantoprazole 40 mg every 24 h for 48 h (standard dose group)
Study: 27637734
Drug: Intravenous pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pantoprazole 40 mg every 12 h for 48 h (double-dose group)
Study: 25435217
Drug: 125 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 μg ocriplasmin intravitreal injection
Study: 23295056
Drug: Adefovir-lamivudine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir-lamivudine combination
Study: 18786751
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg/d, followed by vitamin E 300 mg/d after 6 months, and homocysteine-lowering therapy (folic acid 5 mg/d, pyridoxine 100 mg/d, vitamin B12 1 mg/d) for another year.
Study: 9419397
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (2.0 g daily)
Study: 3611169
Drug: Biodegradable implants
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biodegradable implants (polylactide-glycolide copolymer)
Study: 30652982
Drug: Lumbosacral orthosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbosacral orthosis with routine physical therapy
Study: 29024857
Drug: High-density negative
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-density negative air ions (30 or 60 min daily exposure)
Study: 26910503
Drug: Dual treatment
Normalized name: Meradimate/Octinoxate/Titanium Dioxide Topical application Lotion [PURPOSE DUAL TREATMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual treatment with rilpivirine plus boosted darunavir (DRV)
Study: 26910503
Drug: Triple treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple treatment (standard cART)
Study: 12018757
Drug: Nicotine transdermal
Normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine transdermal system (NTS)
Study: 12018757
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bupropion SR and NTS
Study: 10432175
Drug: Rapid-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-acting insulin analogues
Study: 2089297
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg oestriol vaginal cream for 90 days
Study: 22106979
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 8 mg / Pioglitazone 30 mg
Study: 22106979
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 8 mg / Pioglitazone 15 mg
Study: 22106979
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 4 mg / Pioglitazone 30 mg
Study: 22106979
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 4 mg / Pioglitazone 15 mg
Study: 22106979
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 8 mg / Pioglitazone 0 mg
Study: 22106979
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 0 mg / Pioglitazone 30 mg
Study: 22106979
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 0 mg / Pioglitazone 0 mg